TY - JOUR
T1 - Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models
AU - Schilling, Gabriele
AU - Klevytska, Alexandra
AU - Tebbenkamp, Andrew T.N.
AU - Juenemann, Katrin
AU - Cooper, Jillian
AU - Gonzales, Victoria
AU - Slunt, Hilda
AU - Poirer, Michelle
AU - Ross, Christopher A.
AU - Borchelt, David R.
PY - 2007/4
Y1 - 2007/4
N2 - Huntington disease (HD) is caused by the expansion of a glutamine (Q) repeat near the N terminus of huntingtin (htt), resulting in altered conformation of the mutant protein to produce, most prominently in brain neurons, nuclear and cytoplasmic inclusion pathology. The inclusions and associated diffuse accumulation of mutant htt in nuclei are composed of N-terminal fragments of mutant protein. Here, we used a panel of peptide antibodies to characterize the htt protein pathologies in brain tissues from human HD, and a transgenic mouse model created by expressing the first 171 amino acids of human htt with 82Q (htt-N171-82Q). In tissues from both sources, htt pathologic features in nuclei were detected by antibodies to htt peptides 1-17 and 81-90 but not 115-129 (wild-type huntingtin numbering with 23 repeats). Human HEK 293 cells transfected with expression vectors that encode either the N-terminal 233 amino acids of human htt (htt-N233-82Q) or htt-N171-18Q accumulated smaller N-terminal fragments with antibody-binding characteristics identical to those of pathologic peptides. We conclude that the mutant htt peptides that accumulate in pathologic structures of human HD and httN171-82Q in mice are produced by similar, yet to be defined, proteolytic events in a region of the protein near or within amino acids 90-115.
AB - Huntington disease (HD) is caused by the expansion of a glutamine (Q) repeat near the N terminus of huntingtin (htt), resulting in altered conformation of the mutant protein to produce, most prominently in brain neurons, nuclear and cytoplasmic inclusion pathology. The inclusions and associated diffuse accumulation of mutant htt in nuclei are composed of N-terminal fragments of mutant protein. Here, we used a panel of peptide antibodies to characterize the htt protein pathologies in brain tissues from human HD, and a transgenic mouse model created by expressing the first 171 amino acids of human htt with 82Q (htt-N171-82Q). In tissues from both sources, htt pathologic features in nuclei were detected by antibodies to htt peptides 1-17 and 81-90 but not 115-129 (wild-type huntingtin numbering with 23 repeats). Human HEK 293 cells transfected with expression vectors that encode either the N-terminal 233 amino acids of human htt (htt-N233-82Q) or htt-N171-18Q accumulated smaller N-terminal fragments with antibody-binding characteristics identical to those of pathologic peptides. We conclude that the mutant htt peptides that accumulate in pathologic structures of human HD and httN171-82Q in mice are produced by similar, yet to be defined, proteolytic events in a region of the protein near or within amino acids 90-115.
KW - Huntingtin
KW - Huntington disease
KW - Inclusion bodies
KW - Neurodegenerative disease
KW - Proteolytic processing
UR - http://www.scopus.com/inward/record.url?scp=34147179928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34147179928&partnerID=8YFLogxK
U2 - 10.1097/nen.0b013e318040b2c8
DO - 10.1097/nen.0b013e318040b2c8
M3 - Article
C2 - 17413322
AN - SCOPUS:34147179928
SN - 0022-3069
VL - 66
SP - 313
EP - 320
JO - Journal of neuropathology and experimental neurology
JF - Journal of neuropathology and experimental neurology
IS - 4
ER -